Literature DB >> 9463844

Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness.

J H Gilmore1, L F Jarskog, J C Lindgren, J P McEvoy, H Xiao.   

Abstract

Neurotrophin-3 (NT-3) may have a potential role in the pathogenesis of schizophrenia, given evidence of abnormal neurodevelopment in schizophrenia, as well as a potential association of an NT-3 gene polymorphism with schizophrenia. Cerebrospinal fluid NT-3 protein was assayed using an enzyme-linked immunosorbent assay in five patients with schizophrenia and 49 patients with medical illness. None of the patients with schizophrenia had detectable levels of NT-3 (above 4.7 pg/ml). Eleven samples from 10 different patients with medical or neurological illness had detectable levels of NT-3, associated with surgery for hydrocephalus or central nervous system infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463844     DOI: 10.1016/s0165-1781(97)00116-9

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

Review 1.  Serum growth factors and neuroprotective surveillance: focus on IGF-1.

Authors:  I Torres-Aleman
Journal:  Mol Neurobiol       Date:  2000-06       Impact factor: 5.590

2.  Risperidone Reduces Matrix Metalloproteinase-9 and Increases Neurotrophin-3 in Schizophrenia Spectrum of Disorder.

Authors:  Raghavi Chenniappan; Hanumanthappa Nandeesha; Shivanand Kattimani; Alladi Charanraj Goud; Durgadevi Thiagarajan
Journal:  Indian J Clin Biochem       Date:  2021-06-21

3.  Dysregulation of the fibroblast growth factor system in major depression.

Authors:  S J Evans; P V Choudary; C R Neal; J Z Li; M P Vawter; H Tomita; J F Lopez; R C Thompson; F Meng; J D Stead; D M Walsh; R M Myers; W E Bunney; S J Watson; E G Jones; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-13       Impact factor: 11.205

4.  Elevated nerve growth factor and neurotrophin-3 levels in cerebrospinal fluid of children with hydrocephalus.

Authors:  F Hochhaus; P Koehne; C Schäper; O Butenandt; U Felderhoff-Mueser; E Ring-Mrozik; M Obladen; C Bührer
Journal:  BMC Pediatr       Date:  2001-08-24       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.